WINTON GROUP Ltd - BRAINSTORM CELL THERAPEUTICS ownership

BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 55 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q1 2020. The put-call ratio across all filers is 0.47 and the average weighting 0.0%.

Quarter-by-quarter ownership
WINTON GROUP Ltd ownership history of BRAINSTORM CELL THERAPEUTICS
ValueSharesWeighting
Q4 2020$54,000
-96.7%
11,975
-87.7%
0.00%
-92.6%
Q3 2020$1,649,000
+24.2%
97,455
-17.8%
0.05%
+58.8%
Q2 2020$1,328,000
+272.0%
118,487
+53.9%
0.03%
+277.8%
Q1 2020$357,000
+32.2%
76,967
+21.9%
0.01%
+125.0%
Q4 2019$270,000
-7.8%
63,128
-15.9%
0.00%
+33.3%
Q3 2019$293,00075,0710.00%
Other shareholders
BRAINSTORM CELL THERAPEUTICS shareholders Q1 2020
NameSharesValueWeighting ↓
Ikarian Capital, LLC 189,935$311,4940.08%
ABNER HERRMAN & BROCK LLC 280,000$4590.07%
Weaver Consulting Group 65,947$108,1530.06%
S.C. Financial Services, Inc. 25,372$41,6100.03%
JMAC ENTERPRISES LLC 40,430$66,3050.02%
Weaver Consulting Group 53,500$10,0470.01%
IFP Advisors, Inc 26,650$1390.00%
Bangor Savings Bank 4,000$70.00%
INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC 3,000$4,9200.00%
BOOTHBAY FUND MANAGEMENT, LLC 19,098$31,3210.00%
View complete list of BRAINSTORM CELL THERAPEUTICS shareholders